UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	. FILING DATE		FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/578,013	05/03/2006		Robert F. Garry	129200013PCUS00	3051
23369 7590 06/28/2007 HOWREY LLP C/O IP DOCKETING DEPARTMENT				EXAMINER	
				KINSEY, NICOLE	
	TEW PARK DRIVE, SUITE 200 JRCH, VA 22042-7195			ART UNIT	PAPER NUMBER
		- 1111		1648	
	· .			MAIL DATE	DELIVERY MODE
				06/28/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)					
	10/578,013	GARRY, ROBERT F.					
Office Action Summary	Examiner	Art Unit					
	Nicole E. Kinsey, Ph.D.	1648					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING D. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period of Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUN 36(a). In no event, however, may will apply and will expire SIX (6) M . cause the application to become	NICATION. a reply be timely filed ONTHS from the mailing date of this communication. ABANDONED (35 U.S.C. § 133).					
Status		·					
1) Responsive to communication(s) filed on <u>03 May 2006</u> .							
,							
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Closed in accordance with the practice under t	in parte Quayre, 1000 c						
Disposition of Claims							
4) Claim(s) 1-25 is/are pending in the application 4a) Of the above claim(s) is/are withdra 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) 1-25 are subject to restriction and/or	wn from consideration.						
Application Papers							
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) accomposed and applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the Example 11.	epted or b) objected drawing(s) be held in abertion is required if the drawing	vance. See 37 CFR 1.85(a). ng(s) is objected to. See 37 CFR 1.121(d).					
Priority under 35 U.S.C. § 119							
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.							
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	Paper	w Summary (PTO-413) No(s)/Mail Date of Informal Patent Application					

Art Unit: 1648

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions, which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claims 1-6, having the technical feature of a method for identifying a compound using a viral fusion initiation region (FIR).

Group II, claims 7-12, having the technical feature of an isolated peptide comprising a FIR.

Group III, claims 13 and 16, having the technical feature of treating or preventing a viral infection by administering a compound identified by the method of Group I.

Group IV, claim 14, having the technical feature of treating or preventing a viral infection by administering a peptide of Group II.

Group V, claim 15, having the technical feature of treating or preventing a viral infection by administering a recombinant DNA molecule that enables or simulates production of a FIR.

Group VI, claims 17-18, having the technical feature of an isolated antibody.

Group VII, claim 19, having the technical feature of an isolated nucleic acid.

Group VIII, claims 20-23, having the technical feature of a method for producing an antibody.

Group IX, claims 24-25, having the technical feature of a method of identifying a viral fusion initiation region.

Art Unit: 1648

The inventions listed as Groups I-IX do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Groups II-IX do not have a shared technical feature, and thus, lack unity with each other. The technical feature shared among the inventions listed as Groups I and III is a method for identifying a compound using a viral fusion initiation region (FIR). The noted shared technical feature does not provide a contribution over the prior art, as evidenced by the teachings of Atabani et al. (Journal of Virology, 1997, 71(10):7240-7245). Tables 2 and 3 of Atabani et al. disclose a peptide, which appears to be a functional segment of the FIR of SEQ ID NO:6. Atabani et al. teaches using this peptide as a target compound to identify binding antibodies from virus-induced antisera (Figure 1) and peptide-induced antisera (Table I). Atabani et al. further teaches using the identified anti-peptide antibodies to prevent infection in cultured cells (Table I) and in nonhuman patients (Figure 3). Hence, in the absence of a contribution over the prior art, the noted shared technical feature is not a shared special technical feature. Without a shared special technical feature, the inventions listed as Groups I and III lack unity with one another.

Further Restriction

If applicant elects Group II, applicant is further required to elect **one** of the 20 polypeptide sequences listed in claims 10-12 (SEQ ID NOs: 1-15, 22-25 and 30).

Although the sequences share the function of being fusion initiation regions, the

Art Unit: 1648

in Control Hamber: 10/0/0/0,0

sequences do not share a common core sequence, and thus, lack unity with each other.

This is not a species election.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Nicole E. Kinsey, Ph.D. whose telephone number is (571) 272-9943. The examiner can normally be reached on Monday through Friday from 8:00 am to 5:30 pm.

Art Unit: 1648

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell can be reached on (571) 272-0974. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Nicole E. Kinsey, Ph.D. Examiner
Art Unit 1648

/nk/

/Stacy B. Chen/ 6-25-2007 Primary Examiner, TC1600